AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

AbCellera Biologics Inc.NASDAQ: ABCL

Total Equity · Q3 FY2026 · quarter ended Sep 2026

Total equity rises 10.2% from a year ago

Total equity stood at $1.06B at the end of Q3 FY2026, up 10.2% from a year earlier and up 18.6% from the prior quarter. Over 3 fiscal years it compounded at -7.8% a year.

Context

  • Total equity amounted to 70.8% of total assets at the end of Q3 FY2026, down 0.3 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +10.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.06B+18.6% QoQ
Last fiscal yearDec 2025
$966.9M-8.4% YoY
Year agoSep 2025
$964.04M+10.2% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.2%——
1 year-8.4%——
3-year CAGR-7.8%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
966.9M USD
Year-over-year change
-8.4%
4-year CAGR
-1.5%

Total Equity vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's Sep 2026 total equity of $1.06B is the highest of the 4 companies compared; the peer median is $443.15M.
  • Its year-over-year change of +10.2% is the highest of 3, against a peer median of -22.5%.
  • Total equity amounts to 70.8% of total assets for ABCL, versus a peer median of 82.3%.
ABCL Competitors Peer median
Total Equity for ABCL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABCLAbCellera Biologics Inc.Sep 2026$1.06B +10.2%-7.8%70.8%
GENBGenerate Biomedicines, Inc.Mar 2026$514.8M ——82.3%
DNAGinkgo Bioworks Holdings, Inc.Mar 2026$443.15M -31.6%-33.6%42.9%
ABSIAbsci CorporationMar 2026$171.97M -13.5%-11.6%87.9%
Peer median (excluding ABCL) $443.15M-22.5%-22.6%82.3%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents476.14M386.54M133.32M156.33M128.51M
Short-term Investments246.84M499.95M627.27M469.29M405.31M
Net Receivables174.86M103.41M64.38M92.13M153.4M
Inventory1.67M1.53M1.11M06.34M
Other Current Assets25M25M45.91M33.63M34.67M
Total Current Assets929.8M1.03B871.99M751.37M728.23M
Property, Plant & Equipment (Net)111.62M217.26M287.7M340.43M428M
Goodwill47.81M47.81M47.81M47.81M47.81M
Intangible Assets148.39M131.5M120.43M42.11M38.38M
Long-term Investments50.31M72.52M65.94M82.3M62.58M
Tax Assets7.41M5.3M000
Other Non-current Assets23.23M41.03M94.24M96.54M51.95M
Total Non-current Assets388.77M515.42M616.11M609.18M628.72M
Total Assets1.32B1.54B1.49B1.36B1.36B
Account Payables14.92M14.83M25.51M34.35M25.23M
Short-term Debt00000
Tax Payables35.68M0000
Deferred Revenue7.54M21.61M18.96M21.18M22.51M
Other Current Liabilities54.85M69.84M60.68M8.09M0
Total Current Liabilities120.68M118.32M119.01M76.61M64.31M
Long-term Debt00000
Deferred Tax Liabilities37.37M33.18M30.61M10.05M9.12M
Deferred Revenue (Non-current)60.76M60.32M104.11M155.59M174.45M
Other Non-current Liabilities37.62M19.14M10.82M1.47M4.77M
Total Non-current Liabilities172.16M189.31M216.76M227.86M325.74M
Total Liabilities292.84M307.63M335.78M304.47M390.05M
Common Stock722.43M734.37M753.2M777.17M802.34M
Retained Earnings267.67M426.19M279.79M116.93M(29.48M)
Accumulated OCI280K(1.39M)(1.72M)(4.38M)(4.23M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.03B1.23B1.15B1.06B966.9M
Total Debt40.07M82.26M77.38M65.36M143.22M
Net Debt(436.08M)(304.28M)(55.94M)(90.96M)14.71M

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.